These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 7042087

  • 1. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
    Glick JH, Barnes JM, Bakemeier RF, Prosnitz LR, Bennett JM, Neiman RS, Costello W, Orlow EL.
    Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alternating drug combinations in the treatment of advanced Hodgkin's disease.
    Santoro A, Bonadonna G, Bonfante V, Valagussa P.
    N Engl J Med; 1982 Apr 01; 306(13):770-5. PubMed ID: 6174865
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
    [Abstract] [Full Text] [Related]

  • 9. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):19-30. PubMed ID: 17097834
    [Abstract] [Full Text] [Related]

  • 10. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 11. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R.
    Cancer Treat Rep; 1984 Dec 20; 68(7-8):947-51. PubMed ID: 6204754
    [Abstract] [Full Text] [Related]

  • 12. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF, Anderson JR, Costello W, Rosner G, Horton J, Glick JH, Hines JD, Berard CW, DeVita VT.
    Ann Intern Med; 1984 Oct 20; 101(4):447-56. PubMed ID: 6089632
    [Abstract] [Full Text] [Related]

  • 13. European experience with ifosfamide in lymphomas.
    von Kalle AK, Schaadt M, Diehl V.
    Semin Oncol; 1989 Feb 20; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [Abstract] [Full Text] [Related]

  • 14. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.
    Carella AM, Carlier P, Congiu A, Occhini D, Nati S, Santini G, Pierluigi D, Giordano D, Bacigalupo A, Damasio E.
    Bone Marrow Transplant; 1991 Aug 20; 8(2):99-103. PubMed ID: 1718517
    [Abstract] [Full Text] [Related]

  • 15. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease.
    Brusamolino E, Castelli G, Pagnucco G, Orlandi E, Malagó D, Lazzarino M, Bernasconi C.
    Haematologica; 1990 Aug 20; 75(4):340-5. PubMed ID: 1703510
    [Abstract] [Full Text] [Related]

  • 16. Chemotherapy for advanced Hodgkin's disease: conclusions from the Southeastern Cancer Study Group.
    Gams RA, Durant JR, Bartolucci AA.
    Cancer Treat Rep; 1982 Apr 20; 66(4):899-905. PubMed ID: 7042089
    [Abstract] [Full Text] [Related]

  • 17. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.
    Sangre (Barc); 1998 Jun 20; 43(3):179-84. PubMed ID: 9741222
    [Abstract] [Full Text] [Related]

  • 18. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 19. Conclusions from clinical trials of the Southwest Oncology Group.
    Jones SE, Coltman CA, Grozea PN, DePersio EJ, Dixon DO.
    Cancer Treat Rep; 1982 Apr 15; 66(4):847-53. PubMed ID: 6176321
    [Abstract] [Full Text] [Related]

  • 20. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep 15; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.